Autoantibodies to Glutamic Acid Decarboxylase and Insulin in Islet Cell Antibody Positive Presymptomatic Type 1 Diabetes Mellitus: Frequency and Segregation by Age and Gender

1994 ◽  
Vol 11 (9) ◽  
pp. 866-871 ◽  
Author(s):  
P.Z. Zimmet ◽  
R.B. Elliott ◽  
I.R. Mackay ◽  
T. Tuomi ◽  
M.J. Rowley ◽  
...  
2017 ◽  
Vol 51 (1) ◽  
pp. 1-7 ◽  
Author(s):  
I. Ates ◽  
M. F. Arikan ◽  
K. Erdogan ◽  
M. Kaplan ◽  
M. Yuksel ◽  
...  

Abstract Objective. The aim of the present study was to determine the irisin levels in patients with the type 1 diabetes mellitus (T1DM) and to examine the relation of irisin levels with the inflammation and autoimmunity.Methods. This study included 35 cases diagnosed with T1DM and 36 healthy volunteers. Antiglutamic acid decarboxylase (anti-GAD), islet cell antibody (ICA), and insulin autoantibody levels were measured in patients at the time when they were included into the study and recorded from the patient files. Serum irisin levels were measured by ELISA kit.Results. The median irisin levels were determined higher in T1DM group compared to the control one (6.8 ng/ml vs. 4.8 ng/ml, p=0.022; respectively). Median irisin levels were higher in anti-GAD (p=0.022) and ICA (p=0.044) positive groups compared to negative groups. In T1DM group, irisin levels displayed positive correlation with glycosylated hemoglobin (HbA1c) (r=0.377, p<0.001) and anti-GAD (r=0.392, p=0.020) and negative correlation with creatinine (r=-0390, p=0.021). In multivariate regression model, HbA1c (B±SE: 2.76±17683, p<0.001), and anti-GAD (B±SE: 2.311±0.610, p=0.001) were determined as independent predictors for predicting the irisin levels.Conclusion. In patients with T1DM, which chronic inflammation and autoimmunity take part in their etiopathogenesis, anti-GAD levels were an independent risk factor for the irisin. Th is may suggest that factors such as inflammation and autoimmunity can be effective in the synthesis of irisin.


2011 ◽  
Vol 2011 ◽  
pp. 1-4
Author(s):  
Matsuo Taniyama ◽  
Akira Kasuga ◽  
Chieko Nagayama ◽  
Koichi Ito

Glutamic acid decarboxylase antibodies (GADAs) are one of the markers of islet cell autoimmunity and are sometimes present before the onset of type 1 diabetes (T1D). GADA can be present in Graves' patients without diabetes; however, the outcome of GADA-positive Graves' patients is not fully understood, and the predictive value of GADA for the development of T1D in Graves' patients remains to be clarified. We investigated the prevalence of GADA in 158 patients with Graves' disease and detected GADA in 10 patients. They were followed up to discover whether or not T1D developed. In the course of eight years, 2 patients with high titers of GADA developed T1D, both had long-standing antithyroid drug-resistant Graves' disease. Thus, Graves' disease with high GADA titer seems to be at high risk for T1D.


Sign in / Sign up

Export Citation Format

Share Document